Literature DB >> 12558344

Varicella in non-immune persons: incidence, hospitalization and mortality rates.

P Y Boëlle1, T Hanslik.   

Abstract

This study was conducted to estimate the varicella morbidity and mortality rates per age group among the non-immune population in France. Morbidity and mortality data for the years 1990-9 were derived from nationwide databases and surveillance systems. An incidence/prevalence model was designed to quantify the non-immune population per age group. The incidence of varicella in the non-immune population peaks during childhood and again in the 25-35 years age group. For children aged 1-4 years, adults aged 25-34 years and those older than 65 years, the hospitalization rates are respectively 235, 1,438 and 8,154 per 100,000 cases, and the death rates are respectively 7, 104 and 5,345 per million cases. Case fatality or case hospitalization rates were not evenly distributed among adults and increased dramatically with age.

Entities:  

Mesh:

Year:  2002        PMID: 12558344      PMCID: PMC2869923          DOI: 10.1017/s0950268802007720

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  32 in total

1.  Routine immunization of adults in Canada: Review of the epidemiology of vaccine-preventable diseases and current recommendations for primary prevention.

Authors:  Michael D Parkins; Shelly A McNeil; Kevin B Laupland
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

Review 2.  Should the UK introduce varicella vaccine?

Authors:  Marion Roderick; Athimalaipet V Ramanan; Adam Finn
Journal:  Arch Dis Child       Date:  2007-11-08       Impact factor: 3.791

3.  Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.

Authors:  Markus Knuf; Fred Zepp; Klaus Helm; Hartwig Maurer; Albrecht Prieler; Dorothee Kieninger-Baum; Martine Douha; Paul Willems
Journal:  Eur J Pediatr       Date:  2011-09-21       Impact factor: 3.183

Review 4.  Successes and challenges in varicella vaccine.

Authors:  Orestis Papaloukas; Georgia Giannouli; Vassiliki Papaevangelou
Journal:  Ther Adv Vaccines       Date:  2014-03

5.  Safety and immunogenicity of Bio Pox™, a live varicella vaccine (Oka strain) in Indian children: A comparative multicentric, randomized phase II/III clinical trial.

Authors:  Anand Prakash Dubey; Mohammad Moonis Akbar Faridi; Monjori Mitra; Iqbal Rajinder Kaur; Aashima Dabas; Jaydeep Choudhury; Mallar Mukherjee; Devendra Mishra
Journal:  Hum Vaccin Immunother       Date:  2017-05-16       Impact factor: 3.452

6.  Clinical benefits of routine varicella vaccination for adults.

Authors:  Cinzia Germinario; Maria Serena Gallone; Maria Giovanna Cappelli; Silvio Tafuri
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 7.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

8.  Outbreak of chickenpox in a refugee camp of northern Thailand.

Authors:  Yusuke Shimakawa; Olivier Camélique; Koya Ariyoshi
Journal:  Confl Health       Date:  2010-02-22       Impact factor: 2.723

9.  The burden of varicella in Germany. Potential risks and economic impact.

Authors:  Kurt Banz; Stefan Wagenpfeil; Albrecht Neiss; Thomas Hammerschmidt; Peter Wutzler
Journal:  Eur J Health Econ       Date:  2004-02

Review 10.  Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency.

Authors:  Niklaus H Mueller; Donald H Gilden; Randall J Cohrs; Ravi Mahalingam; Maria A Nagel
Journal:  Neurol Clin       Date:  2008-08       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.